• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Taylor Glen A

    3/13/25 4:06:56 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    TAYLOR GLEN A

    (Last) (First) (Middle)
    C/O 4875 WHITE BEAR PARKWAY

    (Street)
    WHITE BEAR LAKE MN 55110

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Envoy Medical, Inc. [ COCH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 2,953,607 D
    Class A Common Stock 2,526,058 I By Taylor Sports Group(1)
    Class A Common Stock 4,810,384 I By GAT Funding, LLC(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Preferred Stock $11.5 (3) (3) Class A Common Stock 869,565 1,000,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $1.24 02/27/2024 02/27/2026 Class A Common Stock 500,000 500,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $3.04 05/23/2024 02/27/2026 Class A Common Stock 250,000 250,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $2.25 07/22/2024 02/27/2026 Class A Common Stock 250,000 250,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $2.97 08/27/2024 08/27/2026 Class A Common Stock 500,000 500,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $2.2 12/11/2024 08/27/2026 Class A Common Stock 500,000 500,000 I GAT Funding, LLC(2)
    Warrant (right to buy) $1.35 03/11/2025 A(4) 750,000 03/11/2025 03/11/2028 Class A Common Stock 750,000 $0 750,000 I GAT Funding, LLC(2)
    Explanation of Responses:
    1. The Reporting Person is the owner and chairman of Taylor Sports Group.
    2. GAT Funding, LLC is an entity controlled by the Reporting Person.
    3. Fully exercisable and there is no expiration date.
    4. In connection with the promissory note issuance effective March 6, 2025 and the closing of the initial funding on March 11, 2025, this warrant was issued to GAT Funding, LLC, as described in more detail in Item 1.01 of the Issuer's 8-K as filed with the SEC on March 12, 2025.
    /s/ Andrew Nick as Attorney-in-Fact for Glen A. Taylor pursuant to a Power of Attorney previously filed 03/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $COCH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical

      The Esteem(R) device by Envoy Medical is the only totally implantable active middle ear implant with FDA Approval currently on the marketWhite Bear Lake, Minnesota--(Newsfile Corp. - June 26, 2025) - Envoy Medical, Inc. (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that five Category III CPT codes for totally implantable active middle ear implants approved by the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel will be effective on July 1st 2025. CPT codes are used by healthcare professionals and insurers to identify, track, and pay for medical se

      6/26/25 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Life Sciences Investor Forum: Now Available for Online Viewing

      NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

      6/13/25 8:35:00 AM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th

      WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025. DATE: June 12th TIME: 3pm EasternLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th through the 17th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the da

      6/11/25 8:30:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    SEC Filings

    See more
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      6/25/25 8:30:16 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      6/3/25 4:00:26 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      5/19/25 8:52:08 AM ET
      $COCH
      Industrial Specialties
      Health Care